Helmholtz Gemeinschaft


Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis

Item Type:Article
Title:Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis
Creators Name:Stein, U. and Arlt, F. and Smith, J. and Sack, U. and Herrmann, P. and Walther, W. and Lemm, M. and Fichtner, I. and Shoemaker, R.H. and Schlag, P.M.
Abstract:Colon cancer metastasis is often associated with activation of the Wnt/beta-catenin signaling pathway and high expression of the metastasis mediator S100A4. We previously demonstrated the transcriptional regulation of S100A4 by beta-catenin and the importance of the interconnection of these cellular programs for metastasis. Here we probe the hypothesis that the nonsteroidal anti-inflammatory drug sulindac sulfide can inhibit colon cancer metastasis by intervening in beta-catenin signaling and thereby interdicting S100A4. We treated colon cancer cell lines heterozygous for gain-of-function and wild-type beta-catenin with sulindac. We analyzed sulindac's effects on beta-catenin expression and subcellular localization, beta-catenin binding to the T-cell factor (TCF)/S100A4 promoter complex, S100A4 promoter activity, S100A4 expression, cell motility, and proliferation. Mice intrasplenically transplanted with S100A4-overexpressing colon cancer cells were treated with sulindac. Tumor growth and metastasis, and their beta-catenin and S100A4 expressions, were determined. We report the expression knockdown of beta-catenin by sulindac, leading to its reduced nuclear accumulation. The binding of beta-catenin to TCF was clearly lowered, resulting in reduced S100A4 promoter activity and expression. This correlated well with the inhibition of cell migration and invasion, which could be rescued by ectopic S100A4 expression. In mice, sulindac treatment resulted in reduced tumor growth in the spleen (P = .014) and decreased liver metastasis in a human colon cancer xenograft model (P = .025). Splenic tumors and liver metastases of sulindac-treated mice showed lowered beta-catenin and S100A4 levels. These results suggest that modulators of beta-catenin signaling such as sulindac offer potential as antimetastatic agents by interdicting S100A4 expression.
Keywords:Antineoplastic Agents, Cell Movement, Colonic Neoplasms, Liver, Neoplasm Metastasis, Neoplastic Gene Expression Regulation, Non-Steroidal Anti-Inflammatory Agents, S100 Proteins, Signal Transduction, Spleen, Sulindac, TCF Transcription Factors, Transcriptional Activation, Wnt Proteins, beta Catenin, Animals, Mice
Publisher:Neoplasia Press
Page Range:131-144
Date:February 2011
Official Publication:https://doi.org/10.1593/neo.101172
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library